News coverage about Insmed (NASDAQ:INSM) has been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Insmed earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 47.5855797949435 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Insmed (INSM) opened at $24.91 on Thursday. The company has a market cap of $1,946.86, a P/E ratio of -8.71 and a beta of 1.13. Insmed has a one year low of $11.49 and a one year high of $33.94. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.72 and a current ratio of 8.72.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Friday, February 23rd. The biopharmaceutical company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.18). research analysts forecast that Insmed will post -3.65 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Insmed (INSM) Given Media Impact Rating of 0.13” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/15/insmed-insm-given-media-impact-rating-of-0-13/2036895.html.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.